Major Finding: Patients with type 2 diabetes and cardiovascular risk factors who took metformin had a 24% decrease in the risk of death over a 2-year period.
Data Source: A subanalysis of the international REACH Registry, focusing on 19,699 patients with type 2 diabetes.
Disclosures: The registry is sponsored by Sanofi-Aventis, Bristol-Myers Squibb, and the Waksman Foundation, Tokyo. Dr. Roussel disclosed that he has received research support or consulting fees from Sanofi-Aventis, Servier Laboratories, Roche, Eli Lilly & Co., Novo Nordisk Inc., Medtronic Inc., and LifeScan Inc.
From the annual scientific sessions of the American Diabetes Association
PREVIEW